Practical guidelines for the use of long-acting injectable second-generation antipsychotics

被引：13

作者：

Jarema, Marek ^{[1
]}

Wichniak, Adam ^{[1
]}

Dudek, Dominika ^{[2
]}

Samochowiec, Jerzy ^{[3
]}

Bienkowski, Przemyslaw ^{[4
]}

Rybakowski, Janusz ^{[5
]}

机构：

[1] III Psychiat Clin, Inst Psychiat & Neurol Warsaw, PL-02957 Warsaw, Poland

[2] Jagiellonian Univ, Coll Med, Chair Psychiat, Dept Affect Disorders, PL-31007 Krakow, Poland

[3] Pomeranian Med Univ, Dept Psychiat, Szczecin, Poland

[4] Inst Psychiat & Neurol, Dept Pharmacol, Warsaw, Poland

[5] Poznan Univ Med Sci, Dept Adult Psychiat, Poznan, Poland

来源：

PSYCHIATRIA POLSKA | 2015年 / 49卷 / 02期

关键词：

schizophrenia; long-acting antipsychotics; arpiprazole; olanzapine; paliperidone; risperidone; guidelines for use; DOUBLE-BLIND; SCHIZOPHRENIA; ARIPIPRAZOLE; DRUGS; HOSPITALIZATION; FORMULATIONS; OUTCOMES; DEPOT;

D O I：

10.12740/PP/39370

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Long-acting injectable antipsychotics constitute a valuable alternative for the treatment of psychotic disorders, mainly schizophrenia. They assure a more stable drug level, improve treatment compliance, and increase the chances for favorable and long-lasting improvement. Additionally, the long-acting second-generation antipsychotics combine the values of long-acting injectable drugs with the values of atypical antipsychotics. Four second generation long-acting antipsychotics have been described: risperidone, olanzapine, aripiprazole and paliperidone. The indications for their use, treatment strategy, tolerance, and potential interactions are discussed.

引用

页码：225 / 241

页数：17

共 50 条

[31] Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia Practical Considerations
Kverno, Karan
Rozenberg, Ilya
JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2021, 59 (07) : 7 - 12
[32] Long-Acting Injectable Antipsychotics in the ElderlyGuidelines for Effective Use
Prakash S. Masand
Sanjay Gupta
Drugs & Aging, 2003, 20 : 1099 - 1110
[33] Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use
Manchanda, Rahul
Chue, Pierre
Malla, Ashok
Tibbo, Phil
Roy, Marc-Andre
Williams, Richard
Iyer, Srividya
Lutgens, Danyael
Banks, Nicola
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2013, 58 (05): : 5S - 13S
[34] Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes
Fernandez-Miranda, Juan Jose
Diaz-Fernandez, Silvia
Cepeda-Piorno, Francisco Javier
Lopez-Munoz, Francisco
BIOMEDICINES, 2024, 12 (01)
[35] Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics (vol 10, 931, 2020)
Pompili, Maurizio
FRONTIERS IN PSYCHIATRY, 2020, 11
[36] Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations
Schoretsanitis, Georgios
Meyer, Jonathan M.
Conca, Andreas
Hiemke, Christoph
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (04) : 189 - 202
[37] Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents (vol 32, pg 241, 2018)
Jann, Michael W.
Penzak, Scott R.
CNS DRUGS, 2018, 32 (06) : 603 - 603
[38] LONG-ACTING INJECTABLE ANTIPSYCHOTICS Reply
Limandri, Barbara J.
JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2019, 57 (11) : 5 - +
[39] Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches
Hojlund, Mikkel
Correll, Christoph U.
EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (13) : 1463 - 1489
[40] Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method
Rothe, Philipp H.
Heres, Stephan
Leucht, Stefan
SCHIZOPHRENIA RESEARCH, 2018, 193 : 23 - 28

← 1 2 3 4 5 →